Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA

On May 30, 2024, Eckert & Ziegler successfully held its second annual Boston Radionuclide Theranostics Forum. The event reaffirmed the company's key role in radiopharmaceuticals by gathering leading experts, partners, and industry players to discuss the dynamic radiotheranostics market.

The forum addressed solutions to challenges in healthcare system readiness, isotope production, and the development of radiopharmaceuticals. This year's event attracted a larger audience, reflecting the growing interest in this sector. Dr. Harald Hasselmann, CEO, highlighted the discussions' focus on new developments and future market challenges, aiming to advance precision oncology globally.

Initiated and sponsored by Eckert & Ziegler, the forum is now a notable event in nuclear medicine. It featured talks from over a dozen international experts and executives, engaging attendees in dynamic panel discussions. The full-capacity event underscores its importance as a platform for innovation in radiotheranostics.

The third edition of the forum is scheduled for May 29, 2025. Eckert & Ziegler remains dedicated to fostering collaboration in the radiotheranostics field to improve patient outcomes worldwide.